What is Thrive Bioscience?
Thrive Bioscience specializes in automated live cell imaging solutions, providing researchers with advanced tools for quantitative biology. Their flagship products include the Thrive IQ software platform and the CellAssist family of imaging systems, which facilitate the collection and analysis of multidimensional data on live cells, colonies, and organoids. The company aims to empower biologists and data scientists by transforming cell behavior into AI-ready data sets, enhancing experimental efficiency and reproducibility. Thrive Bioscience serves clients in the biotechnology and pharmaceutical sectors, focusing on improving computational models and bioprocessing workflows.
How much funding has Thrive Bioscience raised?
Thrive Bioscience has raised a total of $18.9M across 7 funding rounds:
Multiple Rounds
$9.4M
Private Equity
$7.2M
Debt
$1.8M
Debt
$150K
Debt
$319K
Angel/Seed (2015): $3.3M, investors not publicly disclosed
Angel/Seed (2015): $4M, investors not publicly disclosed
Debt (2015): $2.2M, investors not publicly disclosed
Private Equity (2016): $7.2M, investors not publicly disclosed
Debt (2017): $1.8M, investors not publicly disclosed
Debt (2020): $150K with participation from PPP
Debt (2021): $319K led by PPP
What's next for Thrive Bioscience?
With a substantial enterprise-level funding history and a recent strategic investment, Thrive Bioscience is well-positioned for significant growth and market expansion. The company's focus on transforming cell behavior into AI-ready data sets aligns with the increasing demand for advanced computational biology tools in the biotech and pharmaceutical industries. This capital infusion will likely fuel further research and development, enhance their product offerings, and strengthen their market presence, enabling them to better serve clients seeking to improve bioprocessing workflows and computational models.
See full Thrive Bioscience company page
